Published in Medical Letter on the CDC and FDA, June 24th, 1996
For exposure incidents that are associated with a low or negligible risk of HIV transmission, antiretroviral prophylaxis may not be necessary. The CDC has recommended that zidovudine be included in all chemoprophylaxis antiretroviral regimens. Treatment should be initiated promptly after exposure, preferably within one or two hours. Details were included in the CDC's Morbidity and Mortality Weekly Report (MMWR 1996;45:468-472).
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA